1. Home
  2. EVGO vs IMMP Comparison

EVGO vs IMMP Comparison

Compare EVGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGO

EVgo Inc.

HOLD

Current Price

$1.36

Market Cap

195.6M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$4.74

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGO
IMMP
Founded
2010
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.6M
42.4M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
EVGO
IMMP
Price
$1.36
$4.74
Analyst Decision
Buy
Hold
Analyst Count
8
3
Target Price
$5.23
★ $5.50
AVG Volume (30 Days)
★ 3.4M
341.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.39
N/A
EPS
N/A
★ N/A
Revenue
★ $54,588,000.00
N/A
Revenue This Year
$16.45
$445.09
Revenue Next Year
$29.44
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 145.74
N/A
52 Week Low
$1.23
$0.26
52 Week High
$5.18
$5.36

Technical Indicators

Market Signals
Indicator
EVGO
IMMP
Relative Strength Index (RSI) 44.10 92.30
Support Level $1.23 $2.65
Resistance Level $1.53 N/A
Average True Range (ATR) 0.08 0.09
MACD -0.00 0.44
Stochastic Oscillator 22.29 85.50

Price Performance

Historical Comparison
EVGO
IMMP

About EVGO EVgo Inc.

EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: